Deep Expertise in Chemistry and Structure-based Drug Design Drives Pipeline of Highly Selective Compounds
Kinase inhibition is a proven approach to fighting cancer, and for nearly two decades has addressed an increasing number of oncology indications. At Kinnate, we have a highly experienced drug hunting team to advance novel programs into the clinic that are differentiated, and target validated drivers. We focus on four key parameters in our molecule design: high selectivity, optimized pharmaceutical properties, broad alteration coverage including overcoming resistance or achieving brain penetrance.
Through this approach, we aim to develop product candidates with therapeutic windows that provide durable and meaningful clinical responses to benefit patients in three patient populations:
- those with cancers that harbor known oncogenic drivers with no currently available targeted therapies;
- those with genomically well-characterized tumors that have intrinsic resistance to currently available treatments; and
- those whose tumors have acquired resistance over the course of therapy to currently available treatments.
By focusing on these well-characterized patient populations, we believe we will have a more efficient development path with a greater likelihood of success.
Due to advancements in genomic profiling and relationships with our collaborating precision medicine cancer centers and leading research institutions, we have established and continue to develop a deep expertise and understanding of specific oncogenic drivers.
A Focused Pipeline
We have developed a proprietary portfolio of small molecule candidates targeting validated drivers of cancer.
RAF / exarafenib Monotherapy
BRAF-Driven Advanced Adult Solid Tumors
RAF / exarafenib Combination
Advanced NRAS Mutant Melanoma
Exarafenib (KIN-2787) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor. Unlike currently available treatments that target only Class I BRAF kinase mutations, exarafenib is designed to target BRAF Class II and Class III alterations, where it has the potential to be a first-line targeted therapy, in addition to covering BRAF Class I alterations, and as a potential treatment for NRAS mutation-positive melanoma. KN-8701 is an ongoing, global Phase 1 clinical trial (NCT04913285) evaluating exarafenib in patients with advanced solid tumors harboring BRAF Class I, II and III alterations, and/or who have NRAS mutant melanoma. KN-8701 contains a two-part dose escalation: Part A1 is evaluating exarafenib as a monotherapy across BRAF alterations and tumor types, and Part A2 is evaluating exarafenib in combination with binimetinib, a MEK inhibitor. Part B, dose expansion, is evaluating exarafenib at the recommended dose and schedule in patients with BRAF-altered cancers including lung cancer, melanoma and other solid tumors1.
FGFR2/3 / KIN-3248
Naïve + Pre-treated FGFR2/3 Driven Advanced Adult Solid Tumors
MAPK-Driven Advanced Adult Solid Tumors
Brain Penetrant MEK
c-Met-Driven Advanced Adult Solid Tumors
c-MET, Covers Acquired Resistance
CDK12 / KIN004
Adult Solid Tumors
“Kinnate’s targeted approach will fill a significant unmet need and potentially bring better precision therapies to patients with cancer. As an SAB member, I look forward to working closely with the Kinnate team to advance its pipeline of innovative kinase inhibitors.”
– Ezra Cohen, MD, FRCPSC, FASCO, Kinnate SAB Member